QualityStocks'  Instablog

QualityStocks
Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
QualityStocks
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • AtheroNova, Inc. (AHRO) Welcomes Fred Knoll To Board Of Directors 0 comments
    Nov 8, 2012 8:26 AM | about stocks: AHRO

    Biotech company AtheroNova today announced Fred Knoll, the principal and portfolio manager of Knoll Capital Management, as the newest member to the board of directors of AtheroNova.

    Knoll has served in his current position at Knoll Capital since 1987, and was previously employed as an investment manager for General American Investors; was the U.S. representative on investments in leveraged buyouts and venture capital for Murray Johnstone Ltd. of Glasgow, UK; and was head of the New York investment group of UK-based Robert Fleming Inc., which was acquired by JP Morgan.

    "As a leading investment manager, Fred brings a wealth of knowledge in emerging growth companies and will bring his expertise to our many opportunities as we transition into the next phase of clinical development at AtheroNova," Thomas W. Gardner, CEO of AtheroNova stated in the press release. "We welcome Fred to our board and look forward to working together as we develop AtheroNova's atherosclerosis regression and lipid modulation technology."

    Knoll holds a Bachelor of Science in electrical engineering and computer science from Massachusetts Institute of Technology (MIT.), a Bachelor of Science in management from the Sloan School at MIT, and an MBA from Columbia University in finance.

    AtheroNova operates through its wholly owned subsidiary, AtheroNova Operations, to focus on the discovery, research, development, and licensing of novel compounds to reduce or regress atherosclerotic plaque deposits and to safely improve lipid profiles in humans. The company plans to develop multiple applications for its patents-pending therapies in market sectors that include: cardiovascular disease, stroke, peripheral artery disease, dementia and Alzheimer's, and erectile dysfunction, all of which have been linked to atherosclerosis.

    For more information visit AtheroNova.com

    Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net

    Stocks: AHRO
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.